In the phase I PCD4989 g trial, including a mTNBC cohort treated with atezolizumab monotherapy, the BLIA and LAR subtypes, characterized by higher levels of immune biomarkers (tumor infiltrating lymphocytes (TILs), PD-L1, and CD8 IHC expression) compared to M and BLIS tumors according to Burstein, benefitted most from atezolizumab [28]. The gene discussed is CD8A; the disease is neoplasm.